loader from loading.io

Immersive Precision Neurotherapy for Stroke and Parkinson’s Rehabilitation with Zach Henderson MindMaze Therapeutics TRANSCRIPT

Empowered Patient Podcast

Release Date: 06/30/2026

Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki TRANSCRIPT show art Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki TRANSCRIPT

Empowered Patient Podcast

Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight.   ...

info_outline
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki show art Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki

Empowered Patient Podcast

Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight.   ...

info_outline
Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health TRANSCRIPT show art Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health TRANSCRIPT

Empowered Patient Podcast

Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an...

info_outline
Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health show art Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health

Empowered Patient Podcast

Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an...

info_outline
Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO TRANSCRIPT show art Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO TRANSCRIPT

Empowered Patient Podcast

Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop...

info_outline
Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO show art Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO

Empowered Patient Podcast

Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop...

info_outline
Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI TRANSCRIPT show art Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI TRANSCRIPT

Empowered Patient Podcast

Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI...

info_outline
Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI show art Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI

Empowered Patient Podcast

Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI...

info_outline
Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS TRANSCRIPT show art Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS TRANSCRIPT

Empowered Patient Podcast

Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS,  a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support.  The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver...

info_outline
Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS show art Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS

Empowered Patient Podcast

Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS,  a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support.  The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver...

info_outline
 
More Episodes

Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care.

Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."  

"So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate."

#MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech

MindMazeTherapeutics.com

Listen to the podcast here

MindMaze